FDA Rx Risk Advisor Seligman Joins From DoE, Reports To CDER's Galson
Department of Energy Deputy Assistant Secretary for Health Studies Paul Seligman, MD, will handle pharmaceutical risk management initiatives at FDA in his new position as senior advisor.
You may also be interested in...
Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months
FDA's Office of Postmarketing Drug Risk Assessment will be transferred out of the Office of Review Management to report directly to CDER Deputy Steven Galson, MD, under a reorganization proposal.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011